Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

Inclusion Criteria: * Participate in the clinical trial "NCT05065892". * ≥60 years old individuals with full civil capacity. * Clinically confirmed body temperature of \<37.3°C before enrolling in this study. * Able and willing to participate in the study plan during the entire study and follow-up period. * Capable of understanding the study procedures, willing to sign the informed consent form, and able to comply with the requirements of the clinical study protocol. * Inclusion criteria for patients with hypertension and/or diabetes: Hypertension and/or diabetes definitively diagnosed by a community-level or higher medical institution. Patients with hypertension: systolic pressure \<160 mmHg and diastolic pressure \<100 mmHg on the day of immunization achieved by lifestyle adjustment and/or drug treatment; patients with diabetes: fasting glucose ≤13.9 mmol/L on the day of (or within 3 days before) immunization achieved by lifestyle adjustment and/or drug treatment Exclusion Criteria: * Previously confirmed or asymptomatic COVID-19 patient. * Has been immunized with a SARS-CoV-2 vaccine. * Illiterate. * Known allergy to any ingredient (including excipient) of this product. * Received non-specific immunoglobulin injection within 1 month before enrollment. * Received a live attenuated vaccine within 1 month before immunization or other vaccine within 14 days before immunization. * Previous serious allergy to vaccine (e.g., acute allergic reaction, urticaria, angioedema, and dyspnea). * Has uncontrolled epilepsy and other progressive neurological disorders; history of Guillain-Barré syndrome. * Severe respiratory disorders, severe hepatic and renal diseases, malignancies, and various acute diseases or acute onset of chronic diseases. * Diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, or other autoimmune diseases. * Definitively diagnosed with thrombocytopenia or history of other coagulation disorders that may cause subcutaneous injection to be contraindicated. * Currently experiencing acute complications (ketoacidosis, hyperosmolar state, lactic acidosis, etc.) of diabetes; or within 2 weeks after recovery from these complications. * Other physical conditions judged by the investigator that render the patient unsuitable for participation in the clinical study.